A Phase 2 interventional study of ABT-494 and Placebo in Rheumatoid Arthritis, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-24.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 2, and was the 2nd registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–65
AbbVie
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 276 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 19 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 16th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2013, is one of 16 in phase 2, and was the 38th registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, from their registry updates:
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to anti-TNF biologic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo twice daily (BID) for 12 weeks.
Drug: Placebo
ABT-494 3 mg twice daily (BID) for 12 weeks.
Drug: ABT-494
ABT-494 6 mg twice daily (BID) for 12 weeks.
Drug: ABT-494
ABT-494 12 mg twice daily (BID) for 12 weeks.
Drug: ABT-494
ABT-494 18 mg twice daily (BID) for 12 weeks.
Drug: ABT-494
ABT-494 capsule administered orally twice daily (BID).
Placebo for ABT-494 capsule administered orally twice daily (BID).
Number of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
Response defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hs CRP). Last observation carried forward (LOCF) was used for missing data.
Time frame: Baseline (Week 0) and Week 12
Number of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Week 12
Response defined as at least 50% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hs CRP. LOCF was used.
Time frame: Baseline (Week 0) and Week 12
Number of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 12
Response defined as at least 70% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hs CRP. LOCF was used.
Time frame: Baseline (Week 0) and Week 12
Number of Subjects Achieving Low Disease Activity (LDA) Based on Disease Activity Score (DAS28) or Clinical Remission (CR) Based on (DAS28) at Week 12
LDA is defined as DAS28 from 2.6 to \< 3.2 at Week 12. CR is defined as DAS28 (CRP) \< 2.6 at Week 12. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hs CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. LOCF was used.
Time frame: Baseline (Week 0) and Week 12
Number of Subjects Achieving CR Based on DAS28 at Week 12
The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hs CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. LOCF was used.
Time frame: Baseline (Week 0) and Week 12
| Milestone | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID |
|---|---|---|---|---|---|
| Started | 56 | 55 | 55 | 55 | 55 |
| Completed | 45 | 51 | 46 | 51 | 50 |
| Not completed | 11 | 4 | 9 | 4 | 5 |
| Withdrew: Subject noncompliant | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 6 | 2 | 2 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 1 | 1 | 1 | 0 |
| Withdrew: Consent withdrawn by subject | 3 | 1 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 | 2 |
Response defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hs CRP). Last observation carried forward (LOCF) was used for missing data.
| Participants | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID |
|---|---|---|---|---|---|
| Number of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 19 | 30 | 33 | 40 | 39 |
Response defined as at least 50% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hs CRP. LOCF was used.
| Participants | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID |
|---|---|---|---|---|---|
| Number of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Week 12 | 9 | 13 | 20 | 24 | 22 |
Response defined as at least 70% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hs CRP. LOCF was used.
| Participants | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID |
|---|---|---|---|---|---|
| Number of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 12 | 2 | 7 | 14 | 12 | 12 |
LDA is defined as DAS28 from 2.6 to \< 3.2 at Week 12. CR is defined as DAS28 (CRP) \< 2.6 at Week 12. The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hs CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. LOCF was used.
| Participants | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID |
|---|---|---|---|---|---|
| Number of Subjects Achieving Low Disease Activity (LDA) Based on Disease Activity Score (DAS28) or Clinical Remission (CR) Based on (DAS28) at Week 12 | 14 | 18 | 20 | 29 | 25 |
The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hs CRP, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission. LOCF was used.
| Participants | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID |
|---|---|---|---|---|---|
| Number of Subjects Achieving CR Based on DAS28 at Week 12 | 7 | 13 | 14 | 18 | 17 |
Collected over Treatment-emergent AEs (TEAEs) were collected from first dose of study drug until up to 30 days after discontinuation of study drug (up to 16 weeks); SAEs were collected from the time informed consent was obtained (20 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo BID | 0/56 (0%) | 1/56 (1.8%) | 9/56 (16.1%) |
| ABT-494 3 mg BID | 0/55 (0%) | 2/55 (3.6%) | 13/55 (23.6%) |
| ABT-494 6 mg BID | 0/55 (0%) | 2/55 (3.6%) | 9/55 (16.4%) |
| ABT-494 12 mg BID | 0/55 (0%) | 0/55 (0%) | 14/55 (25.5%) |
| ABT-494 18 mg BID | 0/55 (0%) | 1/55 (1.8%) | 27/55 (49.1%) |
| Event | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID |
|---|---|---|---|---|---|
| PANCREATITISGastrointestinal disorders | 0/56 | 1/55 | 0/55 | 0/55 | 0/55 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 0/56 | 0/55 | 1/55 | 0/55 | 0/55 |
| BENIGN PROSTATIC HYPERPLASIAReproductive system and breast disorders | 0/56 | 0/55 | 1/55 | 0/55 | 0/55 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 0/56 | 0/55 | 0/55 | 0/55 | 1/55 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/56 | 1/55 | 1/55 | 0/55 | 0/55 |
| DEEP VEIN THROMBOSISVascular disorders | 0/56 | 0/55 | 1/55 | 0/55 | 0/55 |
| BRONCHIECTASISRespiratory, thoracic and mediastinal disorders | 1/56 | 0/55 | 0/55 | 0/55 | 0/55 |
| Event | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID |
|---|---|---|---|---|---|
| URINARY TRACT INFECTIONInfections and infestations | 2/56 | 2/55 | 1/55 | 2/55 | 7/55 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 0/56 | 0/55 | 0/55 | 0/55 | 5/55 |
| CONSTIPATIONGastrointestinal disorders | 0/56 | 1/55 | 1/55 | 0/55 | 4/55 |
| NAUSEAGastrointestinal disorders | 1/56 | 4/55 | 1/55 | 2/55 | 4/55 |
| PYREXIAGeneral disorders | 0/56 | 1/55 | 0/55 | 0/55 | 4/55 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/56 | 2/55 | 1/55 | 4/55 | 4/55 |
| LEUKOPENIABlood and lymphatic system disorders | 0/56 | 0/55 | 0/55 | 3/55 | 1/55 |
| GASTROENTERITISInfections and infestations | 1/56 | 0/55 | 0/55 | 0/55 | 3/55 |
| SINUSITISInfections and infestations | 3/56 | 3/55 | 0/55 | 1/55 | 1/55 |
| HYPERLIPIDAEMIAMetabolism and nutrition disorders | 1/56 | 0/55 | 2/55 | 1/55 | 3/55 |
| Age, Continuous(years) | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID | Total |
|---|---|---|---|---|---|---|
| Mean | 57.5 ± 12.04 | 57 ± 13.06 | 56.3 ± 11.71 | 59.1 ± 11.4 | 56.7 ± 12.39 | 57.3 ± 12.12 |
| Sex: Female, Male(Participants) | Placebo BID | ABT-494 3 mg BID | ABT-494 6 mg BID | ABT-494 12 mg BID | ABT-494 18 mg BID | Total |
|---|---|---|---|---|---|---|
| Female | 48 | 43 | 43 | 45 | 42 | 221 |
| Male | 8 | 12 | 12 | 10 | 13 | 55 |
No study locations are listed for this record.
Plan to share: Undecided
Ran from Oct 2013 to primary completion in Jul 2015, 21 months.
Results were first posted in Jun 2018, 2 years 11 months after primary completion. A results delay was requested in Jun 2016.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib